D5 Antibody drug conjugates: Where have we come from? Future opportunities

Wednesday 13 September 2017
COEX Convention & Exhibition Center : Grand Ballroom 101 + 102 3 hours

Organised by the FIP Programme Committee and the FIP Special Interest Group on PK/PD & Systems Pharmacology

Chairs: Don Mager (University at Buffalo, USA)


The recent approval of two antibody-drug conjugates (ADCs) has reinvigorated the approach of safely delivering small molecule cytotoxic agents using targeted monoclonal antibodies in the treatment of cancer. The pharmaceutical industry is rapidly developing and evaluating ADCs that include novel antibody targets, cytotoxic payloads and molecular linkers. Pharmacists and pharmaceutical scientists must become familiar with the potential of and challenges to developing and utilising anticancer ADCs. This session will introduce and review ADCs and highlight the current challenges to bringing these complex medicines to patients needing more effective and less toxic agents for treating cancer. 

Learning objectives

At the end of this knowledge-based session, participants will be able to:

  1. Describe important clinical considerations for treating cancer patients with ADCs.
  2. Describe the challenges and potential solutions to managing the complex supply chain for the manufacture and delivery of ADCs.
  3. Describe the biophysical properties that regulate the pharmacokinetics and pharmacodynamics of ADCs.
  4. Identify important factors to consider for developing combinatorial cancer treatments with ADCs. 


14:30 – 15:10

Creating next generation ADCs and solving issues in development 

Chul-Woong Chung (LegoChem Biosciences, Inc., Republic of Korea)

15:10 – 15:50

2. Managing the ADC supply chain

Jyothi Swamy (MilliporeSigma, USA)

15:50 – 16:10 Coffee/tea break

16:10 – 16:50

3. PK/PD and bioanalytical considerations for ADCs 

Don Mager (University at Buffalo, USA)

16:50 – 17:30

4. Q & A, Panel discussion and conclusion by the chair